New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014
New Data on Mutation-Targeting Therapies and Antibiotics
Combining Lumicaftor and Ivacaftor: The Results of TRAFFIC and TRANSPORTa,b
Methods
Results
Results (cont)
Summary
Study of an Investigational S-Nitroglutathione Reductase Inhibitor
Methods
Results
Results (cont)
Doxycycline Adjunctive Therapy
Methods
Clinical Results
Bioactivity Results
Conclusions
Reports on Investigational Mucolytic Agents and CFTR-Directed Therapies
Study of a Novel Mucolytic Agent
Assessing Viscosity
Assessing Transportability
Investigational CFTR Corrector Added to Ivacaftor Treatment
Methods
Methods and Results
Mean Within-Group Changes (Days 0 to 28)
Take-Home Points
Recent Reports on Pseudomonas Incidence and Treatment
Respiratory Microbiologic Trends
Methods and Results
Results
Results (cont)
Long-Term Data From EPIC Study
Results
Conclusions
Predictors of Response to Antibiotic Treatment for Pulmonary Exacerbations
Results (cont)
Conclusions
Introducing the STOP Study on Pulmonary Exacerbations
The STOP Study
Methods
Results
Physician Willingness to Enroll Patients in Interventional Trials
Preexacerbation Clinical Characteristics: STOP
Symptoms and Signs Present on Admission
Inhaled Hypertonic Saline Plus rhDNase
Results
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)